Mitochondrial disease
Conditions
Interventions
None listed
Sponsors
Fujimoto Toshio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria (1) Disease: Mitochondrial disease (2) Patients whose samples have been collected by collaborating research institutions and stored in the NCNP Muscle Repository (3) Patients from whom consent (including opt-out consent) can be obtained for the use of their samples stored in the NCNP Muscle Repository for this study Patients with a confirmed diagnosis based on genetic testing (either mitochondrial DNA or nuclear DNA) As a general rule, the sharing of patient specimens and information shall be based on obtaining consent for secondary use via the Cell Bank Platform. However, in cases where it is difficult to obtain appropriate consent from the patient, sharing will be conducted through an opt-out process.
Exclusion criteria
Exclusion criteria: Exclusion Criteria (1) Patients with infections of HBV, HCV, HIV-1, HIV-2, or HTLV-1* (2) Patients deemed inappropriate for inclusion in this study by the investigators at the collaborating research institutions *This includes individuals who have tested positive for HBV, HCV, HIV-1, HIV-2, or HTLV-1 in past viral tests, with virus levels exceeding the specified thresholds.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of Pluripotency Markers Proliferative Capacity Differentiation Potential Donor Identity Verification Karyotype Analysis Contamination Screening | — |
Contacts
Public ContactYukari Umeyama
General Incorporated Association iD4
Outcome results
None listed